[Role of insulin secretagogues in the treatment of type 2 diabetes].
Type 2 diabetes mellitus is characterised by both insulin resistance and impaired insulin secretion. It is a chronic disease, which progresses over time, essentially due to a progressive failure of B cells. Non-pharmacological approaches including diet modification, weight control and regular exercise form the cornerstone of therapy. In case of failure of life-style approaches, clinicians have to use oral antidiabetic drugs. Amongst the different glucose-lowering agents, two kinds of insulin secretagogues may be used: sulphonylureas or, more recently, glinides (meglitinide derivatives). After having analysed their mechanism of action and pharmacological characteristics, we describe their role in the management of type 2 diabetic patients. Insulin secretagogues can be used as monotherapy, in association with metformin or a glitazone, or even in combination with a basal insulin regimen. Finally, this article briefly discusses the potential of new insulin secretagogues, called incretins. The metabolic effects of glucagon-like peptide-1 (GLP-1) appear very promising, and can be either reproduced by long-acting GLP-1 analogues, or enhanced by inhibitors of dipeptidylpeptidase-IV, an enzyme that destroys GLP-1.